An overview of epithelial growth factor receptor (EGFR) inhibitors in cancer therapy

Area of Science:

• Oncology and Molecular Biology: Focuses on cell surface receptors and intracellular signaling pathways.

Background:

• Epithelial growth factor receptor (EGFR) is a transmembrane protein crucial for cell signaling.
• EGFR-targeted therapies have advanced precision oncology but long-term remission in solid tumors remains a challenge.
• Tumor cells employ various strategies to manipulate EGFR activity, leading to resistance.

Purpose of the Study:

• To provide a comprehensive overview of EGFR's structure, function, and role in cancer development.
• To review current clinical strategies targeting EGFR in various solid tumors.
• To discuss resistance mechanisms and novel therapeutic approaches against EGFR in oncology.

Main Methods:

• Review of preclinical models including cell cultures, xenografts, and mouse models.
• Analysis of clinical specimens to identify EGFR-related oncogenic pathways and resistance mechanisms.
• Synthesis of existing literature on EGFR's role in cancer and clinical trial outcomes.

Main Results:

• EGFR plays a significant role in the initiation and progression of diverse cancers.
• Preclinical models have elucidated key oncogenic pathways and resistance mechanisms associated with EGFR.
• Clinical studies demonstrate the impact of EGFR-targeted therapies across various tumor types.

Conclusions:

• Understanding EGFR's multifaceted role is crucial for developing effective cancer treatments.
• Novel strategies are needed to overcome resistance and improve long-term outcomes in EGFR-targeted therapy.
• Continued research into EGFR pathways holds promise for future cancer therapies.